HHS To Spend $60M Developing Advanced Generic Drug Making Tech

The Biden administration is committing $60 million to develop technology that improves manufacturing of complex generic drugs, the White House announced Tuesday (June 8). The investment aims to reduce America’s reliance on foreign production of critical drug ingredients. With its authority under the Defense Production Act (DPA), HHS will build off of existing public-private partnerships to establish a group that oversees the manufacturing of domestic essential medicines production. The group will first have to select 50-100 essential drugs to focus...